Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Pirtobrutinib is 300 times more selective for BTK versus 98% of other kinases tested in preclinical studies

  80% confidence

• Continued approval for Jaypirca's MCL and CLL/SLL indications may be contingent upon verification and description of clinical benefit in a confirmatory trial

  80% confidence

• BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients

  80% confidence

• Jaypirca is the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor

  80% confidence

• Data from across the pirtobrutinib development program and investigator-led studies reinforce the medicine's unique clinical profile and its potential role across treatment settings and B-cell malignancies

  80% confidence

• Lilly has been pioneering life-changing discoveries for nearly 150 years

  80% confidence